Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
First-line benmelstobart plus anlotinib versus sunitinib in advanced kidney cancer
A new immunotherapy called benmelstobart, which blocks the action of [...]
New immunotherapy for metastatic kidney cancer could help improve outcomes
Researchers from the University of California in Los Angeles (UCLA) [...]
Combination treatment shows benefits in rare, aggressive kidney cancer
Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare [...]
Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Pembrolizumab plus axitinib shows sustained benefit in advanced kidney cancer
The final long-term follow-up data from the phase 3 KEYNOTE-426 [...]
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line treatment for metastatic kidney cancer
Treatment of advanced (metastatic) kidney cancer has improved considerably over [...]
Cabozantinib most promising for refractory metastatic kidney cancer
In a European study of second-line treatments for metastatic kidney [...]
Combination therapy shows promise for hereditary papillary kidney cancer
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated papillary RCC is [...]
UK regulators approve injectable form of nivolumab for solid tumours
The Medicines and Healthcare products Regulatory Agency (MHRA) in the [...]
